BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Naviscan, Inc. Release: Researchers to Present Key Findings Highlighting the Accuracy and Expanding Role of PEM in Breast Cancer Management at ECR 2013


2/26/2013 9:34:35 AM

SAN DIEGO, CA--(Marketwire - February 25, 2013) -

Drs. Muller, Hentschel, Gilman and Farahati will be presenting their data on 68 women with breast lesions found to be suspicious on mammography, which were then evaluated with positron emission mammography (PEM) using the Naviscan, Inc. high-resolution, organ-specific PET scanner. The presentation, titled 'Positron Emission Mammography Is an Accurate Tool in Diagnosis of Breast Cancer,' will be available on EPOS™ - Electronic Presentation Online System for the 2013 European Congress of Radiology to be held March 7 - 11 in Vienna, Austria.

Of the 70 lesions seen on the mammograms, PEM correctly identified all 14 malignancies when an uptake threshold, known as PUVmax, of greater than 2.0 was used. This resulted in a cancer detection sensitivity of 100%, specificity of 94%, a Positive Predictive Value (PPV) of 89%, and Negative Predictive Value (NPV) of 100%. Both PPV and NPV are measure of the modality's accuracy.

The average lesion to background ratio of FDG uptake was 3.4+/-1.6 for cancerous lesions and 1.1+/-0.02 for benign lesions, a statistically significant difference (p=0.001). This pilot study demonstrated that by using PEM and FDG quantitative analysis, breast cancer can be differentiated from benign breast lesions with extremely high accuracy, thereby potentially saving unnecessary biopsies of benign lesions.

About Naviscan PEM Scanner
The Naviscan PEM scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early breast cancer diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.

About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.


Contact Information
Joleen Schultz
Naviscan Marketing Communications
Tel: +1.760-271-8150
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES